Acasti Pharma Says Phase 3 TRILOGY 2 Study Did Not Meet Primary Endpoint - Quick Facts

Biopharmaceutical company Acasti Pharma Inc. (ACST) announced Monday top-line results for the Primary Endpoint (triglyceride reduction at 12 and 26 weeks) from its 278 patient Phase 3 TRILOGY 2 study evaluating the efficacy, safety and tolerability of CaPre in patients with severe hypertriglyceridemia. The study did not meet its primary endpoint.

from RTT - Biotech https://ift.tt/2EGOoAn
via IFTTT